Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | ECE1 | P42892 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.38 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.38 |
| ▸ | ITGAV | P06756 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL628018 | 0.86 | EPHX1 (0.57) | EPHX1TSHRPLA2G2AADRA1AHTT | |
| SCHEMBL4704932 | 0.84 | ADRA1A (0.61) | EPHX1TSHRPLA2G2AADRA1APOLB | |
| SCHEMBL7123668 | 0.82 | ADRA1A (0.64) | EPHX1TSHRPLA2G2AADRA1APOLB | |
| SCHEMBL9828955 | 0.82 | ADRA1A (0.64) | EPHX1TSHRPLA2G2AADRA1APOLB | |
| SCHEMBL6473541 | 0.82 | ADRA1A (0.64) | EPHX1TSHRPLA2G2AADRA1APOLB | |
| SCHEMBL3190326 | 0.81 | EPHX1 (0.61) | EPHX1TSHRTDP1ALDH1A1 | |
| SCHEMBL5949703 | 0.80 | EPHX1 (0.50) | EPHX1TSHRKDM4EALDH1A1 | |
| SCHEMBL13813999 | 0.80 | TSHR (0.57) | EPHX1TSHRHTTKDM4ELMNA | |
| SCHEMBL7255174 | 0.79 | HDAC3 (0.46) | ECE1PLA2G2AHTTEGLN1 | |
| SCHEMBL22735084 | 0.79 | ECE1 (0.42) | ECE1TSHRPLA2G2AADRA1APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009151744-A1 | S-NITROSOMERCAPTO COMPOUNDS AND RELATED DERIVATIVES | GALLEON PHARMACEUTICALS, INC. (US) | 2009-12-17 | — | — | WO | claimed |
| WO-2024043313-A1 | REVERSIBLE THERMOCHROMIC COMPOSITION, MICROENCAPSULATED PIGMENT USING SAID REVERSIBLE THERMOCHROMIC COMPOSITION, WRITING TOOL, AND TOY | 三菱ケミカル株式会社 | 2024-02-29 | — | — | WO | disclosed |
| US-11786605-B2 | Site specific antibody-drug conjugates with peptide-containing linkers | MERSANA THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| EP-4196228-A1 | N-CYCLYL-SULFONAMIDES USEFUL FOR INHIBITING RAF | Albert Einstein College of Medicine (US) | 2023-06-21 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| WO-2022036176-A1 | N-CYCLYL-SULFONAMIDES USEFUL FOR INHIBITING RAF | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2022-02-17 | — | — | WO | disclosed |
| CN-106588890-B | Antiviral compounds | 吉利德制药有限责任公司 | 2020-11-27 | — | — | CN | disclosed |
| EP-3626716-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-03-25 | — | — | EP | disclosed |
| EP-3309157-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2018-04-18 | — | — | EP | disclosed |
| WO-2017223514-A9 | LXR INVERSE AGONISTS FOR TREATMENT OF CANCER | SAINT LOUIS UNIVERSITY (US) | 2018-04-12 | — | — | WO | disclosed |
| WO-2010039793-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-08 | — | — | WO | disclosed |
| WO-2009102633-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-20 | — | — | WO | disclosed |
| WO-2009102694-A1 | HETEROCYCLIC DERIVATIVES AS HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-20 | — | — | WO | disclosed |
| WO-2009102568-A1 | CONFORMATIONALLY RESTRICTED BIPHENYL DERIVATIVES FOR USE AS HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-20 | — | — | WO | disclosed |
| WO-2009102318-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-20 | — | — | WO | disclosed |
| US-20090099061-A1 | SYNTHESIS OF CAROTENOID ANALOGS OR DERIVATIVES WITH IMPROVED ANTIOXIDANT CHARACTERISTICS | CARDAX PHARMACEUTICALS, INC. | 2009-04-16 | — | — | US | disclosed |
| EP-0765879-B1 | 13-Substituted milbemycin 5-oxime derivatives, their preparation and their use against insects and other pests | SANKYO CO (JP) | 2001-02-14 | — | — | EP | disclosed |
| US-5861429-A | MITICIDES AND ANTHELMINTICS | SANKYO COMPANY, LIMITED (JP) | 1999-01-19 | — | — | US | disclosed |
| EP-0765879-A1 | 13-Substituted milbemycin 5-oxime derivatives, their preparation and their use against insects and other pests | SANKYO COMPANY LIMITED (JP) | 1997-04-02 | — | — | EP | disclosed |
| US-5466858-A | Ruthenium catalyst, high selectivity with a carboxylic acid | UBE INDUSTRIES, LTD. (JP) | 1995-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11786605-B2 | Site specific antibody-drug conjugates with peptide-containing linkers | CD2BP2, DNPEP, LNPEP | EPHX1 2454/4885ECE1 2337/4885TSHR 2332/4885 |
| US-20090099061-A1 | SYNTHESIS OF CAROTENOID ANALOGS OR DERIVATIVES WITH IMPROVED ANTIOXIDANT CHARACTERISTICS | CAT, HBZ, POLL | EPHX1 2995/4885ECE1 989/4885TSHR 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.